98%
921
2 minutes
20
Parkinson's disease (PD) is one of the most common neurodegenerative disorders worldwide. Current identification and monitoring of its motor symptoms depends on the clinical expertise. Repetitive finger tapping is one of the most common clinical maneuvers to assess for bradykinesia. Despite the increasing use of technology aids to quantitatively characterize the motor symptoms of PD, there is still a relative lack of clinical evidence to support their widespread use, particularly in low-resource settings. In this pilot study, we used a low-cost design prototype coupled with an inertial sensor is coupled to quantify the frequency of the finger tapping movements in four participants with PD. Repetitive finger tapping was performed using both hands before and after taking levodopa as part of their clinical treatment. The proposed 3D design allowed repetitive movements to be performed without issues. The maximum frequency of finger tapping was in the range of 0.1 to 4.3 Hz. Levodopa was associated with variable changes in the maximum frequency of finger tapping. This pilot study shows the feasibility for low-cost technology to quantitatively characterize repetitive movements in people living with PD.Clinical relevance- In this pilot study, a low-cost inertial sensor coupled to a design prototype was feasible to characterize the frequency of repetitive finger tapping movements in four participants with PD. This method could be used to quantitatively identify and monitor bradykinesia in people living with PD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/EMBC40787.2023.10340532 | DOI Listing |
Endocr Connect
September 2025
Centre for Higher Education Development, University of Cape Town.
Background: Cortisol and growth hormone are important for sleep regulation and cognition. Sleep is critical for cognitive functioning, and memory consolidation. Patients with pituitary disease experience hormonal dysregulation, impaired sleep quality, and cognitive dysfunction.
View Article and Find Full Text PDFBrain Stimul
September 2025
Medical Research Council Brain Network Dynamics Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom. Electronic address:
Background: Precisely timed brain stimulation, such as phase-locked deep brain stimulation (PLDBS), offers a promising approach to modulating dysfunctional neural networks by enhancing or suppressing specific oscillations. However, its clinical application has been hindered by the lack of user-friendly systems and the challenge of real-time phase estimation amid stimulation artifacts.
Material And Method: In this work, we developed a clinically translatable PLDBS framework that enables real-time, cycle-by-cycle stimulation using standard amplifiers and a computer-in-the-loop system.
J Neurophysiol
September 2025
Defitech Chair of Clinical Neuroengineering, Neuro X Institute (INX), École Polytechnique Fédérale de Lausanne (EPFL), Campus Biotech, Geneva, Switzerland.
Complex neural activity of the motor cortex is posited to serve as the foundation for a large repertoire of activation patterns crucial for executing movements. As transcranial magnetic stimulation (TMS) predominantly activates monosynaptic fast-conducting corticospinal projections, which are involved in dexterous movement control, complexity of neural outputs elicited by TMS may reflect an underlying repertoire of activation patterns crucial for executing dexterous movements. We proposed to quantify dimensionality of multi-muscle motor-evoked potentials (MEPs) through dimensionality reduction as an integrated measure to reflect complexity of neural outputs elicited by TMS.
View Article and Find Full Text PDFJ Parkinsons Dis
September 2025
Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.
Individuals with isolated REM sleep behavior disorder (iRBD) are at high risk of developing α-synucleinopathies, particularly Parkinson's disease (PD) and dementia with Lewy bodies (DLB). With the development of potential neuroprotective treatments for synucleinopathies, including PD, identifying clinical features that can allow for tracking subtle changes in prodromal disease and thereby monitoring risk of phenoconversion in iRBD is paramount. Subtle motor deficits have been suggested to be present in iRBD, making them potentially important clinical markers for predicting future phenoconversion.
View Article and Find Full Text PDFMov Disord
September 2025
Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Background: Digital-motor outcomes promise better responsiveness than clinician-reported outcomes in ataxia trials. However, their patient meaningfulness and sensitivity to change remain to be demonstrated, particularly in the upper limb domain.
Objectives: Validation of quantitative motor (Q-Motor) assessment for upper limb ataxia against patient-reported outcomes and regarding sensitivity to both longitudinal and treatment-induced change, the latter in n-of-1 treatment settings.